Rayno Life Science Portfolio Recovers Up 1.73%; Jobless Claims Help
The thrashing of Illumina (ILMN) yesterday appears to be overdone as the stock is recovering to the $60 area on volume of over 3.5M shares as of mid-day trading.The Tools and Diagnostics sector is still weaker than Biopharma due to focus on sales and earnings metrics rather than themes and pipelines. Case in point Life Technologies is down 5.58% on an earnings miss (52c vs 58c). Within the Rayno Portfolio we have strength in the following Tools/Dx stocks: Abaxis(ABAX) up 4.6%, Exact Sciences (EXAS) up 2.13%, Neogen (NEOG) up 2.29%,and Sequenom (SQNM) up 3.59%. ETF’s such as IBB ($105.3)and XBI ($72.12) rallied about 2% above June support levels.
Our biopharma mid-cap index is up 1.5% with only a few losers.Apparently bargain hunters like Exelixis(EXEL) up 5.4% and Optimer (OPTR) up 4.89%.
Larger Cap biotechs are leading the QQQ up 1.14% so we would take profits on the Q’s vs IBB trade started last week. Biotechs leading the Q’s: ILMN,VRTX,CELG, and TEVA.
Regeneron (REGN $55) is up 4.5% on an upgrade.